Selling an Ophthalmology Practice in 2026: Multiples, Named Buyers, and the MSO Playbook

If you own an ophthalmology practice in 2026 — whether that is a single-MD general ophthalmology office, a multi-MD specialty practice, or a small regional group — the M&A market is one of the most active healthcare-services consolidation themes. EyeCare Partners (Partners Group), US Eye (Quad-C Management), US Ophthalmic Partners (Tenex Capital), Retina Consultants of America (Webster Equity Partners), Vision Innovation Partners (Centre Partners), and multiple other PE-backed platforms are aggressively rolling up the sector. The combination of aging-population demand, ASC ownership economics, and predictable patient recurrence makes ophthalmology a structurally attractive PE consolidation theme.

What the asset is worth depends on three things: (1) subspecialty mix (retina commands the highest multiples; oculoplastics and pediatric are premium; cataract-only compresses), (2) ASC ownership and the Stark-compliant structure of any physician-owned ambulatory surgery center, and (3) payer mix, modern EMR, and provider bench depth. This guide covers real multiples by profile, the named buyers transacting, and the operator-level diligence buyers will run.

This guide is about ophthalmology practices (medical and surgical eye care). For pure-play optometry practices (vision-care, refraction, eyewear), see our separate guide at how to sell an optometry practice.

Named ophthalmology M&A transactions (2022-2025)

The named buyer landscape

PE-backed national ophthalmology MSOs (the primary buyer pool)

• EyeCare Partners (Partners Group) — the largest US eye-care MSO with ~700+ providers across optometry and ophthalmology.
• US Eye (Quad-C Management) — multi-state ophthalmology platform.
• US Ophthalmic Partners (Tenex Capital) — multi-state ophthalmology platform.
• Vision Innovation Partners (Centre Partners) — Mid-Atlantic ophthalmology platform.
• Spectrum Vision Partners (Clayton, Dubilier & Rice) — Northeast ophthalmology platform.
• Pinnacle Eye Group (PE-backed) — regional ophthalmology platform.
• AION Healthcare (PE-backed) — multi-state ophthalmology platform.

Retina-specific specialty platforms

• Retina Consultants of America (Webster Equity Partners) — the largest US retina-specific MSO; multi-state.
• Retina Group of Washington, Retina Associates of Cleveland, plus multiple other regional retina platforms with PE backing.

ASC and surgical-platform buyers

• Surgery Partners (NASDAQ: SGRY) — ASC partner; selective acquirer / JV partner for ophthalmology ASC operations.
• USPI (Tenet Healthcare subsidiary) — ASC partner; selective ophth ASC partnerships.

PE sponsors active in this space

• Partners Group (EyeCare Partners), Quad-C Management (US Eye), Webster Equity Partners (Retina Consultants of America), Centre Partners (Vision Innovation Partners), Tenex Capital (US Ophthalmic Partners), CD&R / Clayton, Dubilier & Rice (Spectrum Vision Partners), Audax Group, plus multiple healthcare-services PE funds.

What each buyer will pay for vs. what they reject

• Will pay premium for: subspecialty mix including retina (premium), oculoplastics, pediatric, glaucoma, cornea; ASC ownership with Stark-compliant structure; named commercial in-network contracts (50%+ commercial mix); modern EMR (Nextech is the operator standard, EyeMD, ManagementPlus, Modernizing Medicine EMA-Ophthalmology); provider productivity (25-45 general encounters/day); multi-state professional licensure; documented post-cataract premium IOL (intraocular lens) revenue.
• Will compress or reject: cataract-only practice concentration without subspecialty mix, owner-MD dependence with no succession bench, Stark or anti-kickback exposure on ASC arrangements, weak commercial payer mix (Medicare-heavy above 60%), single-MD-only practices, legacy EMR or paper charts, single-payer concentration above 25%, unaudited financials.

The operator-level KPI playbook buyers will diligence

Subspecialty and service-line mix

• Subspecialty mix: General ophthalmology %, retina %, glaucoma %, cornea %, oculoplastics %, pediatric %, neuro-ophthalmology %. Retina is the premium subspecialty.
• Cataract surgery volume: Cases per year, premium IOL attach rate (toric, multifocal, EDOF). Premium IOL attach is a material multiple-builder.
• Refractive surgery: LASIK, PRK, lens-based refractive volume.
• Injection volume (retina): Anti-VEGF injections (Eylea, Lucentis, Avastin compounded, Vabysmo); track volume, payer mix, drug-cost ratio.

ASC ownership and structure

• ASC ownership: Wholly-owned, joint venture with hospital, JV with Surgery Partners or USPI, in-office surgical suite. Document ownership percentage.
• ASC accreditation: AAAHC, AAAASF, Joint Commission ambulatory.
• Stark and anti-kickback compliance: ASC ownership arrangements must be Stark-compliant; document referral patterns and ownership economics.
• ASC case volume and revenue.

Payer mix and contracting

• Commercial percentage: 50%+ commercial is the platform benchmark.
• Medicare percentage: 35-50% Medicare is typical for ophthalmology (aging-population demand). Above 60% Medicare compresses.
• Medicare Advantage vs. Fee-for-service split.
• In-network status: Anthem/Elevance, UHC, Aetna, Cigna, BCBS-by-state, plus regional payers.
• Single-payer concentration: No single payer above 25%.

Provider productivity

• Encounters per day per MD: General ophthalmology 25-45 encounters/day; retina specialists 25-40; subspecialty varies.
• OD (optometrist) staffing: Many ophth practices use OD providers for initial workup and routine care; document mix.
• RVU productivity: Track wRVU per provider per day.
• Surgical case mix per surgeon.

EMR and operating system

• EMR: Nextech (the ophthalmology operator standard), EyeMD, ManagementPlus, Modernizing Medicine EMA-Ophthalmology, EHR Officemate (Officemate has been challenged).
• Imaging integration: OCT, visual fields (Humphrey), fundus photography, IOL Master, integrated with EMR.
• Patient portal and engagement.

Provider bench and succession

• Provider count and tenure.
• Average MD age and retirement pipeline.
• Provider compensation model.
• Equity rollover / earnout structure expectations: Most PE-MSO deals include 20-40% equity rollover.

RCM

• Days in AR: <40 days is healthy.
• Denial rate: <8% first-pass.
• Drug-cost ratio (retina): Track anti-VEGF drug cost as % of revenue carefully (buy-and-bill economics).

Dangers and traps in ophthalmology M&A

1. Stark and anti-kickback exposure on ASC arrangements

Physician-owned ASC arrangements must be Stark-compliant. Document ASC ownership structure, referral patterns, and economic terms.

2. Cataract-only practice concentration

Cataract-only practices have lower multiples than diversified subspecialty practices. Retina, oculoplastics, pediatric, glaucoma, and cornea subspecialty exposure are multiple-builders.

3. Owner-MD dependence with no succession

If the practice is single-MD-dependent and the MD is close to retirement, build the provider bench 2-3 years out.

4. Anti-VEGF drug-cost ratio surprises (retina)

Anti-VEGF injection economics depend heavily on payer mix and Medicare ASP+6% pressures. Audit drug-cost ratio carefully; Avastin compounded vs. branded Eylea/Lucentis/Vabysmo mix matters.

5. Premium IOL attach rate accounting

Premium IOL revenue (toric, multifocal, EDOF) is cash-pay or self-pay; document accounting carefully. Premium IOL attach rate is a real multiple-builder when documented.

6. Medicare-heavy payer mix

Above 60% Medicare concentration compresses the multiple. Practices in retirement-community areas often face this.

7. EMR transition exposure

Nextech is the operator standard. Legacy systems or non-integrated EMR with imaging trigger integration discount.

8. OD/MD scope-of-practice and supervision

State-specific rules on OD (optometrist) scope of practice; document OD/MD model carefully.

9. Equity-rollover expectations vs. cash-at-close

PE-MSO ophth deals typically include 20-40% equity rollover. Understand the rollover dynamics before LOI.

10. Real-estate ownership and rent-rate fairness

Many ophth practices own the real estate; get a market-rent appraisal and document a fair-market-value lease structure.

Our POV on ophthalmology M&A in 2026

• Single-MD general ophthalmology practices ($500k-1.5M EBITDA) go 5x-7x EBITDA.
• Multi-MD single-site or 2-3 location practices ($1.5-4M EBITDA) are tuck-in targets for the national MSOs. 6x-9x.
• Small regional groups (3-10 providers, $3-8M EBITDA) are sweet-spot platforms. 7x-10x.
• Mid-size platforms with ASC ownership ($5-15M EBITDA) are highly leveraged. 8x-11x.
• Premium scale platforms ($15M+ EBITDA, multi-state, retina-inclusive subspecialty, ASC ownership, named in-network commercial) reach 10x-14x+.

The right time to prepare is 12-18 months before going to market — build subspecialty (especially retina) exposure, structure Stark-compliant ASC arrangements, modernize EMR (Nextech), develop the provider bench, and document premium IOL attach rate.

Preparing your ophthalmology practice for sale: 12-18 months out

1. Get multi-year audited or reviewed financials. Break out revenue by subspecialty, ASC vs. office, payer mix.
2. Build subspecialty mix. Retina is the premium addition; oculoplastics, pediatric, glaucoma, cornea also premium.
3. Structure Stark-compliant ASC arrangements. Health-care counsel review.
4. Modernize the EMR. Nextech is the operator standard; ensure imaging integration (OCT, fields, fundus).
5. Develop the provider bench and OD/MD model.
6. Document premium IOL attach rate.
7. Confirm commercial in-network status.
8. Document add-backs cleanly.
9. Resolve professional liability matters.
10. Run a competitive process. EyeCare Partners, US Eye (Quad-C), US Ophthalmic Partners (Tenex), Retina Consultants of America (Webster Equity), Vision Innovation Partners (Centre), Spectrum Vision (CD&R), Pinnacle, AION, plus PE sponsors directly (Partners Group, Quad-C, Webster Equity, Centre Partners, Tenex Capital, CD&R, Audax).

The five pillars of how CT Acquisitions works

Frequently asked questions

What is the typical multiple for an ophthalmology practice in 2026?

Single-MD general ophthalmology practices ($500k-1.5M EBITDA) typically sell at 5x-7x. Multi-MD single-site or 2-3 location practices go 6x-9x. Small regional groups (3-10 providers, $3-8M EBITDA) go 7x-10x. Mid-size platforms with ASC ownership ($5-15M EBITDA) go 8x-11x. Premium scale platforms ($15M+ EBITDA, multi-state, retina-inclusive subspecialty, ASC ownership) reach 10x-14x+.

Who are the active buyers of ophthalmology practices right now?

PE-backed national MSOs: EyeCare Partners (Partners Group, ~700+ providers), US Eye (Quad-C Management), US Ophthalmic Partners (Tenex Capital), Vision Innovation Partners (Centre Partners), Spectrum Vision Partners (CD&R / Clayton, Dubilier & Rice), Pinnacle Eye Group, AION Healthcare. Retina-specific: Retina Consultants of America (Webster Equity Partners). ASC partners: Surgery Partners (NASDAQ: SGRY), USPI (Tenet).

What hurts an ophthalmology practice’s valuation most?

Cataract-only practice concentration without subspecialty mix, Stark or anti-kickback exposure on ASC arrangements, owner-MD dependence with no succession bench, Medicare-heavy payer mix above 60%, weak commercial in-network status, legacy EMR or paper charts, single-payer concentration above 25%, and unaudited financials.

Why is retina subspecialty the premium subsegment?

Retina has higher per-encounter revenue (anti-VEGF injection economics), longer patient-relationship recurrence (chronic conditions like AMD and DME), and named PE consolidator activity (Retina Consultants of America under Webster Equity Partners has built a multi-state retina-specific platform). Diversified ophthalmology practices with retina sub-specialty exposure achieve materially higher multiples than cataract-only practices.

How important is ASC ownership?

Very important. ASC (ambulatory surgery center) ownership provides additional EBITDA and a buyer-attractive surgical platform. Stark-compliant ASC ownership structures (group practice exception, ancillary services exception) are required. ASCs add 1-3 turns of EBITDA multiple over no-ASC practices when properly structured.

What is the typical equity rollover in an ophthalmology MSO transaction?

Most PE-MSO ophthalmology deals include 20-40% equity rollover for the selling MDs. The rollover equity participates in the next platform exit (typically 4-7 years out). Understanding the rollover valuation, second-sale terms, and rollover equity rights is critical before signing an LOI.

Do I have to pay a broker fee?

No. CT Strategic Partners runs a buyer-paid M&A advisory model. The seller pays nothing. The buyer pays the success fee at closing.

When should I start preparing if I plan to sell in 2027 or 2028?

12-18 months before going to market is the right window. Highest-leverage pre-sale work: build subspecialty mix (especially retina), structure Stark-compliant ASC arrangements, modernize EMR (Nextech), develop the provider bench, document premium IOL attach rate, and confirm commercial in-network status.

Related research

• How to sell an optometry practice
• How to sell a dermatology practice
• How to sell a MedSpa
• How to sell an urgent care center
• How to sell a physical therapy practice
• How to sell an imaging center
• How to sell a clinical laboratory
• Healthcare business valuation
• Which industries is PE buying most in 2026
• Business broker alternative

About the Author

Christoph Totter is the founder of CT Acquisitions, a buy-side partner headquartered in Sheridan, Wyoming. We work directly with 76+ buyers, search funders, family offices, lower middle-market PE, and strategic consolidators, including direct mandates with the largest home services consolidators that other intermediaries can’t access. The buyers pay us when a deal closes, not the seller. No retainer, no exclusivity, no contract until close. Connect on LinkedIn · Get in touch